Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 19755966 · doi:10.1038/ajg.2009.508
What was done
A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted across multiple databases (MEDLINE, EMBASE, Google Scholar, Cochrane Central Register of Controlled Trials, ACP Journal Club, DARE, Cochrane Methodology Register, HTA Database, and conference abstracts) to compare first-line treatment of Helicobacter pylori infection. The study evaluated bismuth quadruple therapy (PPI, bismuth, tetracycline, metronidazole) versus clarithromycin triple therapy (PPI, clarithromycin, amoxicillin) for efficacy and tolerability. Data were extracted by two independent reviewers, and meta-analysis was performed using Stata 10.1.
What was found
Nine RCTs with 1,679 patients were included. Bismuth quadruple therapy achieved an eradication rate of 78.3%, while clarithromycin triple therapy achieved 77.0% (risk ratio [RR] = 1.002, 95% CI: 0.936–1.073). Moderate heterogeneity was observed and was not explained by subgroup analyses of study location, treatment duration, or study population. There was no statistically significant difference in side effects between quadruple and clarithromycin triple therapy (RR = 1.04, 95% CI: 1.04–1.14).
Why it matters
Both guideline-recommended first-line regimens achieve nearly identical, suboptimal eradication rates below 80% with comparable tolerability and compliance profiles.
Limits
Dosing regimens for bismuth quadruple therapy varied considerably across trials compared to triple therapy. Moderate heterogeneity was present and remained unexplained by subgroup analyses. The abstract does not provide data on local antimicrobial resistance patterns, which strongly influence eradication rates.
Cited by
- supports Approximately 15% of patients treated with triple antibiotic therapy for Helicobacter pylori cannot tolerate it or do not achieve eradication.